Coefficient Bio

• Anthropic announced the acquisition of Coefficient Bio, a U.S.-based AI startup specializing in biological modeling, on April 27, 2026. • The deal aims to integrate Coefficient's protein design AI tools with Anthropic's Claude models for advanced drug discovery applications. • This move positions Anthropic in the competitive AI-biotech space amid rising investments, potentially accelerating personalized medicine breakthroughs.

• Anthropic expanded its AI strategy by acquiring AI drug discovery startup Coefficient Bio for approximately $400 million and launching a political action committee to influence AI regulation. • The company is also seeing surging investor demand for its shares amid tightening AI infrastructure supply and growing market appetite. • These moves position Anthropic to shape policy, enter life sciences, and capitalize on demand for leading AI technologies in the US.

• Anthropic acquired Coefficient Bio, a startup founded eight months ago with fewer than 10 employees, for roughly $400 million in shares, despite it having no product or revenue. • The platform uses AI for pharmaceutical tasks like drug research planning and identifying new drug opportunities, positioning Anthropic's models for scientific discovery in life sciences. • This bet signals a strategic push into AI-driven biotech, potentially accelerating drug development amid growing competition in applied AI verticals.

• Anthropic acquired startup Coefficient Bio for more than $400 million to bolster its AI capabilities amid recent challenges like a source code leak. • The deal follows Anthropic's npm packaging error exposing Claude Code's source code, including memory architecture and model roadmap. • This acquisition strengthens Anthropic's position despite setbacks, potentially aiding future developments in autonomous AI features.